Sartorius Stedim Biotech has disclosed its preliminary financial results for the fiscal year 2024, revealing a net profit of €175.1 million, which signifies a 43.6% decrease compared to the previous year. The earnings per share declined to €1.81 from €3.37. The underlying EBITDA reported a slight decrease of 0.8%, amounting to €779 million, while underlying earnings per share dropped to €3.49 from €4.19.
In terms of sales revenue for 2024, the company reported €2.78 billion, representing a modest increase of 0.2% in reported figures, a 0.6% rise when adjusted for constant currencies, and a 0.7% decline on an organic basis in constant currencies. The order intake witnessed a robust growth, increasing by 12.9% in constant currencies and 12.3% in reported terms.
During the fourth quarter, sales revenue reached €751 million, marking a 6.1% increase in constant currencies and a 6.3% rise in reported figures. The order intake for this period saw a significant surge of 23.8% in constant currencies.
Looking ahead to 2025, the management anticipates achieving profitable, moderate growth surpassing the market average. The company aims to continue profitable growth beyond the market level and expects a moderate increase in sales revenue. Additionally, it projects that the underlying EBITDA will grow at a rate exceeding that of sales revenue.
